Skip to main content

TUMORES DEFICIENTES EN LA CORRECCION DE ERRORES DE LAS POLIMERASAS: PROFUNDIZANDO EN SUS BASES GENETICAS Y BIOLOGIA INMUNE PARA MEJORAR LAS RECOMENDACIONES CLINICAS

PID2020-112595RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACIO INSTITUT D INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Constitutional epimutations in LTBP4, a component of the TGF-β signaling, and in BRCA1, as potential drivers of early-onset colorectal cancer

  • Terradas, Mariona|||0000-0001-7813-1172
  • Mur, Pilar
  • Bousquets-Muñoz, Pablo
  • Puente, Xose S.|||0000-0001-9525-1483
  • Nielsen, Maartje|||0000-0002-5351-1870
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Valle, Laura|||0000-0003-0371-0844
  • Morón-Duran, Francisco D.
  • Mengod, Pol
  • Löffler, Chiara M.L.
  • Helderman, Noah C.
  • Terlouw, Diantha
  • Sanjuán, Xavier
  • Viana-Errasti, Julen
  • Capellá, Gabriel
  • van Wezel, Tom
  • Kather, Jakob Nikolas
Background: Constitutional primary monoallelic promoter methylation of hereditary cancer genes, although rare, may explain early-onset cancers without family history. Also, promoter methylation of a hereditary cancer gene secondary to a genetic alteration in a methylation regulatory region can cause a hereditary cancer syndrome. This study investigates constitutional promoter methylation as mechanism of inactivation of cancer predisposition genes in genetically unsolved familial and/or early-onset colorectal cancer (CRC) patients. Results: Bisulfite-treated peripheral blood DNA from 46 early-onset/familial CRC patients was analyzed using the Illumina Infinium MethylationEPIC BeadChip. One early-onset CRC patient exhibited constitutional, likely monoallelic, methylation of CpG island 102 in LTBP4, a gene involved in TGF-β signaling. Somatic methylation of this CpG island is common in CRC, and correlates with LTBP4 downregulation. LTBP4 double knockout mice develop colorectal adenomas and carcinomas, supporting the role of this gene in CRC predisposition. No additional cases with constitutional LTBP4 CpG island 102 methylation or enrichment of deleterious LTBP4 variants in CRC patients compared to controls were found. Another early-onset CRC patient exhibited mosaic BRCA1 promoter methylation, typically associated with increased breast and ovarian cancer risk. No somatic second hit in BRCA1 was detected in the patient's tumor, and homologous recombination deficiency-associated features were inconclusive. Conclusions: Our findings suggest that constitutional methylation of LTBP4 CpG island 102 may be associated with increased CRC risk. Identification of additional cases is needed to confirm the existence of a novel CRC predisposition syndrome driven by epigenetic inactivation of LTBP4, potentially also linked to other clinical phenotypes associated with LTBP4 deficiency, such as pulmonary emphysema. Whether constitutional BRCA1 methylation contributes to CRC risk remains to be determined.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Wnt genes in colonic polyposis predisposition

  • Quintana, Isabel
  • Tonda, Raúl
  • Parra Farré, Genís
  • Piscia, Davide
  • Beltran, Sergi
  • Valle, Laura
This research was funded by the Spanish Ministry of Science and Innovation (Agencia Estatal de Investigación), and co-funded by FEDER funds a way to build Europe [Grants No. SAF2016-80888-R (LV), PID2020-112595RB-I00 (LV), and PID2019-111254RB-I00 (GC), and predoctoral fellowship “Formación de Personal Investigador” (IQ)]; Instituto de Salud Carlos III [CIBERONC CB16/12/00234, Sara Borrell Postdoctoral contract (PM)]; Government of Catalonia, Spain [PERIS MedPerCan, AGAUR 2017SGR1282, CERCA Program for institutional support]; Scientific Foundation “Asociación Española Contra el Cáncer” [AECC Investigador (MT)]; Marie Skłodowska-Curie Individual Fellowship [Organ-VIP; Grant agreement No. 897064 (NG-A)]. The Solve-RD project is funded by the European Union's Horizon 2020 research and innovation program under grant agreement No. 779257. This study was supported by the European Reference Network on Genetic Tumor Risk Syndromes (ERN GENTURIS) - Project ID No. 739547 (www.genturis.eu), and the COST action CA17118, supported by COST (European Cooperation in Science and Technology).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Evaluation of BoostDM, a somatic variant prediction tool, for the interpretation of germline variants in hereditary cancer genes

  • Munté, Elisabet
  • Muiños, Ferran
  • Marín, Raúl
  • Feliubadaló, Lídia
  • Brando, Federica
  • López Bigas, Núria
  • Lázaro, Conxi
  • González-Pérez, Abel
  • Valle, Laura
Classifying germline variants in hereditary cancer genes remains challenging and requires integrating diverse lines of evidence. BoostDM is a computational method originally developed to identify somatic cancer driver mutations by detecting signals of positive selection. Given the functional overlap between somatic and germline pathogenic variants in cancer genes, we evaluated the utility of BoostDM for interpreting germline variants in hereditary cancer genes. We assessed BoostDM's performance across six genes with dual roles in sporadic and hereditary cancer (ATM, BRCA1, BRCA2, CDH1, PTEN, TP53), using gene-specific BoostDM models. A total of 1275 germline single nucleotide variants with expert-reviewed pathogenic and benign classifications were included. BoostDM scores were compared to those from AlphaMissense and REVEL, two leading pathogenicity predictors for missense variants. BoostDM correctly classified 74.5% of pathogenic/likely pathogenic and 98.6% of non-synonymous benign/likely benign variants overall. It performed particularly well for non-synonymous, non-missense variants (92.3% sensitivity). For missense variants, BoostDM correctly identified 46% of pathogenic and 95.5% of benign variants. While BoostDM did not outperform AlphaMissense or REVEL, it demonstrated high specificity (99.5%) and positive predictive value (PPV = 98%) for missense variants with high scores ( > 0.5). Gene-specific performance varied, with TP53 showing the most robust results. In conclusion, BoostDM predictions are not a replacement for ACMG/AMP-guided germline variant classification, especially for missense changes. However, its high specificity and PPV suggest that high BoostDM scores can provide supportive evidence of pathogenicity, prompting further clinical and functional investigation., This study was funded by the Spanish Ministry of Science and Innovation (Agencia Estatal de Investigación), co-funded by FEDER funds a way to build Europe [PID2024-162582OB-I00; PID2020-112595RB-I00 (AEI/10.13039/501100011033)]; Instituto de Salud Carlos III [PI23/00017; CIBERONC CB16/12/00234 and CB21/12/00013; PMP22/00064, also funded by NextGenerationEU (MRR)/PRTR]; Government of Catalonia [AGAUR 2021SGR01112; CERCA Program for institutional support].
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Lack of evidence for germline WWP1 pathogenic variants in gastrointestinal polyposis and other phenotypes suggestive of PTEN-hamartoma-tumor syndrome

  • Gonzalez-Abuin, Noemi
  • Pons, Tirso
  • Fuster, Teresa
  • Quintana, Isabel
  • Terradas, Mariona
  • Aiza, Gemma
  • Brunet, Joan
  • Capellá, Gabriel
  • Hampel, Heather
  • Valle, Laura
Supplementary data to this article can be found online at https://doi.org/10.1016/j.gendis.2023.03.011., This study was funded by the Spanish Ministry of Science and Innovation (Agencia Estatal de Investigacio ́n), co-funded by FEDER funds -a way to build Europe- [PID2020- 112595RB-I00 (LV)], Instituto de Salud Carlos III (CIBERONC CB16/12/00234), Government of Catalonia (AGAUR 2021SGR01112, CERCA Program for institutional support), Marie Skłodowska-Curie Individual Fellowship (No. 897064 (NG-A)), and Scientific Foundation “Asociación Española Contra el Cáncer" [AECC Investigador contract (MT)]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Comparative Analysis of Somatic and Germline Polymerase Proofreading Deficiencies in Cancer: Molecular and Clinical Implications

  • Viana-Errasti, Julen
  • Marín, Raúl
  • García-Mulero, Sandra
  • Pons, Tirso
  • Terradas, Mariona
  • Capellá, Gabriel
  • Moreno, Victor
  • Mur, Pilar
  • Valle, Laura
Supplementary Material https://www.sciencedirect.com/science/article/pii/S0893395225001401?via%3Dihub#cebib0010:~:text=This,publication, Polymerases ε and δ maintain genome integrity through exonuclease proofreading. Germline and somatic pathogenic variants (PVs) in the exonuclease domain (ED) of POLE and POLD1 impair proofreading, causing hypermutated tumors. Despite shared mutational features that make these tumors highly immunogenic, molecular and clinical distinctions between POLE and POLD1 mutations and between somatic and germline variants remain incompletely understood. We compared the molecular and clinical characteristics of POLE and POLD1 ED PVs (n = 31), assessing their location, pathogenicity, clinical phenotypes, mismatch repair (MMR) status, tumor mutational burden, and signatures. We analyzed 360 proofreading-deficient tumors (source: The Cancer Genome Atlas [TCGA] and Catalogue Of Somatic Mutations In Cancer [COSMIC]) and 70 families (249 individuals) with polymerase proofreading-associated polyposis. All germline and somatic PVs had high AlphaMissense scores (0.87-1) and clustered within or near Exo motifs. Recurrent, nonfounder germline PVs, POLE L424V and POLD1 S478N, showed low/modest REVEL scores. Somatic variants occurred mainly in endometrial cancers (75% of proofreading-deficient TCGA cancers), whereas colorectal cancer predominated in polymerase proofreading-associated polyposis (56% of carriers). Cancer risks and tumor spectra differed between POLE and POLD1 PV carriers. Aggressive hereditary phenotypes were linked to either specific POLE PVs (eg, S297F, V411L, P436R, M444K, A456P, and S461T) or the co-occurrence of germline ED PVs with germline MMR gene PVs. Distinct hypermutator profiles were confirmed for polymerase ε and polymerase δ proofreading deficiencies via unique mutational signatures (Polymerase ε: SBS10a/b, SBS28; Polymerase δ: SBS10c/d). Tumors with combined proofreading and MMR deficiencies had significantly higher tumor mutational burden and a shift in the associated mutational spectra. Unlike POLE, POLD1 ED PVs exhibited haplosufficiency, typically requiring a somatic second hit (eg, loss of heterozygosity) or MMR deficiency to drive hypermutation. In conclusion, differences between POLE and POLD1 and between somatic and germline mutations influence clinical presentation, mutagenic potential, and reliance on cooperating defects in tumorigenesis. These insights advance the understanding of proofreading-deficient cancers, with implications for diagnostics, genetic counseling, and precision oncology., This study was funded by the Spanish Ministry of Science and Innovation (Agencia Estatal de Investigación), cofunded by FEDER funds a way to build Europe (PID2024-162582OB-I00; PID2020-112595RB-I00, AEI/10.13039/501100011033 and “Contrato predoctoral para la formación de doctores” [J.V.-E.]); Instituto de Salud Carlos III [CIBERONC CB16/12/00234; PMP22/00064, also funded by NextGenerationEU (MRR)/PRTR]; Government of Catalonia [AGAUR 2021SGR01112; CERCA Program for institutional support (IDIBELL)]. None of the study sponsors had any involvement in the study design, collection, analysis and interpretation of data, writing of the report and decision to submit the article for publication., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Wnt genes in colonic polyposis predisposition

  • Quintana, Isabel
  • Tonda, Raúl
  • Parra Farré, Genís
  • Piscia, Davide
  • Beltran, Sergi
  • Valle, Laura
This research was funded by the Spanish Ministry of Science and Innovation (Agencia Estatal de Investigación), and co-funded by FEDER funds a way to build Europe [Grants No. SAF2016-80888-R (LV), PID2020-112595RB-I00 (LV), and PID2019-111254RB-I00 (GC), and predoctoral fellowship “Formación de Personal Investigador” (IQ)]; Instituto de Salud Carlos III [CIBERONC CB16/12/00234, Sara Borrell Postdoctoral contract (PM)]; Government of Catalonia, Spain [PERIS MedPerCan, AGAUR 2017SGR1282, CERCA Program for institutional support]; Scientific Foundation “Asociación Española Contra el Cáncer” [AECC Investigador (MT)]; Marie Skłodowska-Curie Individual Fellowship [Organ-VIP; Grant agreement No. 897064 (NG-A)]. The Solve-RD project is funded by the European Union's Horizon 2020 research and innovation program under grant agreement No. 779257. This study was supported by the European Reference Network on Genetic Tumor Risk Syndromes (ERN GENTURIS) - Project ID No. 739547 (www.genturis.eu), and the COST action CA17118, supported by COST (European Cooperation in Science and Technology).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Evaluation of BoostDM, a somatic variant prediction tool, for the interpretation of germline variants in hereditary cancer genes

  • Munté, Elisabet
  • Muiños, Ferran
  • Marín, Raúl
  • Feliubadaló, Lídia
  • Brando, Federica
  • López Bigas, Núria
  • Lázaro, Conxi
  • González-Pérez, Abel
  • Valle, Laura
Classifying germline variants in hereditary cancer genes remains challenging and requires integrating diverse lines of evidence. BoostDM is a computational method originally developed to identify somatic cancer driver mutations by detecting signals of positive selection. Given the functional overlap between somatic and germline pathogenic variants in cancer genes, we evaluated the utility of BoostDM for interpreting germline variants in hereditary cancer genes. We assessed BoostDM's performance across six genes with dual roles in sporadic and hereditary cancer (ATM, BRCA1, BRCA2, CDH1, PTEN, TP53), using gene-specific BoostDM models. A total of 1275 germline single nucleotide variants with expert-reviewed pathogenic and benign classifications were included. BoostDM scores were compared to those from AlphaMissense and REVEL, two leading pathogenicity predictors for missense variants. BoostDM correctly classified 74.5% of pathogenic/likely pathogenic and 98.6% of non-synonymous benign/likely benign variants overall. It performed particularly well for non-synonymous, non-missense variants (92.3% sensitivity). For missense variants, BoostDM correctly identified 46% of pathogenic and 95.5% of benign variants. While BoostDM did not outperform AlphaMissense or REVEL, it demonstrated high specificity (99.5%) and positive predictive value (PPV = 98%) for missense variants with high scores ( > 0.5). Gene-specific performance varied, with TP53 showing the most robust results. In conclusion, BoostDM predictions are not a replacement for ACMG/AMP-guided germline variant classification, especially for missense changes. However, its high specificity and PPV suggest that high BoostDM scores can provide supportive evidence of pathogenicity, prompting further clinical and functional investigation., This study was funded by the Spanish Ministry of Science and Innovation (Agencia Estatal de Investigación), co-funded by FEDER funds a way to build Europe [PID2024-162582OB-I00; PID2020-112595RB-I00 (AEI/10.13039/501100011033)]; Instituto de Salud Carlos III [PI23/00017; CIBERONC CB16/12/00234 and CB21/12/00013; PMP22/00064, also funded by NextGenerationEU (MRR)/PRTR]; Government of Catalonia [AGAUR 2021SGR01112; CERCA Program for institutional support].